[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP1854463A4 - Release-control composition - Google Patents

Release-control composition

Info

Publication number
EP1854463A4
EP1854463A4 EP06715493A EP06715493A EP1854463A4 EP 1854463 A4 EP1854463 A4 EP 1854463A4 EP 06715493 A EP06715493 A EP 06715493A EP 06715493 A EP06715493 A EP 06715493A EP 1854463 A4 EP1854463 A4 EP 1854463A4
Authority
EP
European Patent Office
Prior art keywords
release
control composition
composition
control
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06715493A
Other languages
German (de)
French (fr)
Other versions
EP1854463A1 (en
Inventor
Hajime Ishida
Yukihiro Nomura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of EP1854463A1 publication Critical patent/EP1854463A1/en
Publication of EP1854463A4 publication Critical patent/EP1854463A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP06715493A 2005-03-03 2006-03-03 Release-control composition Withdrawn EP1854463A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005059501 2005-03-03
PCT/JP2006/304672 WO2006093353A1 (en) 2005-03-03 2006-03-03 Release-control composition

Publications (2)

Publication Number Publication Date
EP1854463A1 EP1854463A1 (en) 2007-11-14
EP1854463A4 true EP1854463A4 (en) 2011-03-23

Family

ID=36941373

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06715493A Withdrawn EP1854463A4 (en) 2005-03-03 2006-03-03 Release-control composition

Country Status (5)

Country Link
US (1) US8828429B2 (en)
EP (1) EP1854463A4 (en)
JP (1) JP5159303B2 (en)
CA (1) CA2610343A1 (en)
WO (1) WO2006093353A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113952459A (en) 2005-02-03 2022-01-21 综合医院公司 Methods of treating gefitinib resistant cancers
EP3488866A1 (en) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
AR056888A1 (en) * 2005-12-09 2007-10-31 Speedel Experimenta Ag HIDEROCICLIL IMIDAZOL DERIVATIVES
WO2007092718A2 (en) * 2006-02-07 2007-08-16 Fmc Corporation Coating process to produce controlled release coatings
US8343548B2 (en) 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
US8343547B2 (en) 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
US8519120B2 (en) 2006-08-08 2013-08-27 Shin-Etsu Chemical Co., Ltd. Methods for producing a low-substituted hydroxypropylcellulose powder
JP4827986B2 (en) 2007-06-08 2011-11-30 マンカインド コーポレ−ション IRE-1α inhibitor
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR20100088144A (en) * 2007-10-29 2010-08-06 다케다 야쿠힌 고교 가부시키가이샤 Pyrrolo [1,2-c] imidazole derivatives for use in the prophylaxis or treatment of cancer which is refractory to known cancer therapies
ES2431355T3 (en) 2008-06-17 2013-11-26 Wyeth Llc Antineoplastic combinations containing HKI-272 and vinorelbine
CN107308130B (en) 2009-11-09 2021-06-15 惠氏有限责任公司 Coated drug spheroids and use to eliminate or reduce conditions such as emesis and diarrhea
WO2011083402A2 (en) 2010-01-11 2011-07-14 Muneera Mohamed Shafee Immediate release compositions of acid labile drugs
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
GB201003734D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
BR112012032033A2 (en) * 2010-06-16 2017-10-31 Takeda Pharmaceuticals Usa Inc new modified release xanthine oxidoreductase inhibitor or xanthine oxidase inhibitor dosage forms
GEP20156306B (en) * 2011-04-01 2015-06-25 Takeda Pharmaceutical Solid preparation
EP2606880A1 (en) * 2011-12-23 2013-06-26 LEK Pharmaceuticals d.d. Coating process with aqueous latex coating
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
WO2016124960A1 (en) * 2015-02-08 2016-08-11 Alkermes Pharma Ireland Limited Monomethylfumarate prodrug compositions
JP6832195B2 (en) * 2016-03-03 2021-02-24 ライオン株式会社 Oral liquids and oral solids
CN112390909B (en) * 2020-11-16 2022-09-02 西安工程大学 preparation method and application of pH/salt double-sensitive ether-based functionalized polyion liquid gel

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0356673A2 (en) * 1988-09-02 1990-03-07 FARMITALIA CARLO ERBA S.r.l. Substituted 5,6,7,8-tetrahydroimidazo[1,5-a]pyridines and process for their preparation
EP0426225A2 (en) * 1989-11-01 1991-05-08 Janssen Pharmaceutica N.V. (6,7-dihydro-5H-pyrrolo[1,2-c]-imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1H-benzotriazole derivatives
WO1993015079A1 (en) * 1992-01-27 1993-08-05 Janssen Pharmaceutica N.V. Pyrroloimidazolyl and imidazopyridinyl substituted 1h-benzimidazole derivatives as aromatase inhibitors
WO2002040484A2 (en) * 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Novel imidazole derivatives, production method thereof and use thereof
WO2004082679A1 (en) * 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Release control compositions
EP1471056A1 (en) * 2002-01-10 2004-10-27 Takeda Chemical Industries, Ltd. Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same
EP1477161A1 (en) * 2003-05-16 2004-11-17 Shin-Etsu Chemical Co., Ltd. Pharmaceutical solid preparation containing a poorly soluble drug and production process thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994395A (en) * 1995-02-24 1999-11-30 Novartis Animal Health Us, Inc. Composition for controlling parasites
EP1308160A4 (en) 2000-08-08 2005-01-19 Daiichi Seiyaku Co Highly absorbable solid preparation
JP2002193831A (en) 2000-12-27 2002-07-10 Fancl Corp Hemoferrum-containing composition for oral
CH693586A8 (en) 2002-10-14 2003-12-15 Roche Consumer Health Ag Formulation of ibuprofen sodium.
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
JP4494712B2 (en) 2002-11-12 2010-06-30 大日本住友製薬株式会社 Multiple unit type sustained release formulation
WO2004075890A1 (en) 2003-02-26 2004-09-10 Takeda Pharmaceutical Company Medicinal composition containing stabilized imidazole derivative and method of stabilizing imidazole derivative
JP4837895B2 (en) 2003-03-17 2011-12-14 武田薬品工業株式会社 Controlled release composition
JP2005059501A (en) 2003-08-19 2005-03-10 Seiko Epson Corp Recorder, its controlling method, control program and recording medium
US8486450B2 (en) 2005-12-28 2013-07-16 Takeda Pharmaceutical Company Limited Method of producing solid preparation disintegrating in the oral cavity

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0356673A2 (en) * 1988-09-02 1990-03-07 FARMITALIA CARLO ERBA S.r.l. Substituted 5,6,7,8-tetrahydroimidazo[1,5-a]pyridines and process for their preparation
EP0426225A2 (en) * 1989-11-01 1991-05-08 Janssen Pharmaceutica N.V. (6,7-dihydro-5H-pyrrolo[1,2-c]-imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1H-benzotriazole derivatives
WO1993015079A1 (en) * 1992-01-27 1993-08-05 Janssen Pharmaceutica N.V. Pyrroloimidazolyl and imidazopyridinyl substituted 1h-benzimidazole derivatives as aromatase inhibitors
WO2002040484A2 (en) * 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Novel imidazole derivatives, production method thereof and use thereof
EP1471056A1 (en) * 2002-01-10 2004-10-27 Takeda Chemical Industries, Ltd. Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same
WO2004082679A1 (en) * 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Release control compositions
EP1607092A1 (en) * 2003-03-17 2005-12-21 Takeda Pharmaceutical Company Limited Release control compositions
EP1477161A1 (en) * 2003-05-16 2004-11-17 Shin-Etsu Chemical Co., Ltd. Pharmaceutical solid preparation containing a poorly soluble drug and production process thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200469, Derwent World Patents Index; AN 2004-709798 *
See also references of WO2006093353A1 *

Also Published As

Publication number Publication date
EP1854463A1 (en) 2007-11-14
US8828429B2 (en) 2014-09-09
JP5159303B2 (en) 2013-03-06
JPWO2006093353A1 (en) 2008-08-07
US20090053308A1 (en) 2009-02-26
WO2006093353A1 (en) 2006-09-08
CA2610343A1 (en) 2006-09-08

Similar Documents

Publication Publication Date Title
EP1854463A4 (en) Release-control composition
IL185906A0 (en) Composition
EP1930012A4 (en) Cellooligosaccharide-containing composition
IL184421A0 (en) Fertilizer-compatible composition
PL3327109T3 (en) Composition
EP1865042A4 (en) Frost-preventive composition
GB0618435D0 (en) Composition
IL186778A0 (en) Stabilized composition
EP1847249A4 (en) Hairdye composition
ZA200705932B (en) Fertilizer-compatible composition
EP1947129A4 (en) Photoradial- and photocation-curable composition
GB0508250D0 (en) Composition
EP1864573A4 (en) Agricultural-chemical composition
GB0506044D0 (en) Composition
ZA200707917B (en) Composition
GB0507167D0 (en) Composition
GB0505760D0 (en) Novel composition
GB0502341D0 (en) Composition
HK1101657A2 (en) Novel composition
GB0513641D0 (en) Anti-egeing composition
GB0513367D0 (en) Novel composition
GB0510286D0 (en) Composition
GB0511497D0 (en) Composition
GB0525108D0 (en) Composition
GB0517170D0 (en) Composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070904

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20110222

17Q First examination report despatched

Effective date: 20120216

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/52 20060101ALI20150603BHEP

Ipc: A61K 31/4164 20060101AFI20150603BHEP

Ipc: A61K 47/38 20060101ALI20150603BHEP

Ipc: A61K 47/04 20060101ALI20150603BHEP

Ipc: A61P 35/00 20060101ALN20150603BHEP

Ipc: A61K 47/32 20060101ALI20150603BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/32 20060101ALI20150605BHEP

Ipc: A61K 9/52 20060101ALI20150605BHEP

Ipc: A61K 31/4164 20060101AFI20150605BHEP

Ipc: A61K 47/04 20060101ALI20150605BHEP

Ipc: A61K 47/38 20060101ALI20150605BHEP

Ipc: A61P 35/00 20060101ALN20150605BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150721

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ISHIDA, HAJIME

Inventor name: NOMURA, YUKIHIRO

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20151201